(October 1, 2015, 2:47 PM EDT) -- WASHINGTON, D.C. — In a drug patent infringement lawsuit over Apotex Inc.’s efforts to end Mylan Pharmaceuticals Inc.’s generic exclusivity for “Benicar” hypertension drug, Mylan in a Sept. 8 petition for certiorari asks the U.S. Supreme Court to answer whether a case requirement for Article III of the U.S. Constitution can be satisfied when the suit seeks a judgment of noninfringement of a disclaimed patent (Mylan Pharmaceuticals, Inc. v. Apotex, Inc., No. 15-307, U.S. Sup.)....